An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s disease was presented at the ISSCR 2026 Annual Meeting, marking a significant step for regenerative medicine.
The phase 1b/2a Regen4HD study follows years of preclinical work, safety testing and regulatory engagement aimed at developing new approaches for a condition with no disease‑modifying treatments.
Huntington’s disease is a progressive neurodegenerative disorder. Regenerative strategies using human stem cell‑derived products are being explored as a way to modulate disease pathology and address substantial unmet need.
The presentation highlighted the launch of the first clinical trial of a pluripotent stem cell‑derived therapy for the condition.
Regen4HD is enrolling relatively early‑stage symptomatic patients aged 18 to 65. The phase 1b portion is a dose‑escalation study assessing safety and tolerability, followed by a phase 2a stage to determine the maximum tolerated dose.
Leslie Thompson, PhD, University of California, Irvine, said: “This clinical trial represents the culmination of many years of preclinical and translational research, pivotal safety studies, discussions with the FDA, and support from the California Institute for Regenerative Medicine.”
She continued: “Reaching the point of launching the first clinical trial of a pluripotent stem cell‑derived product for Huntington’s disease is an important milestone for the field.
“The Huntington’s disease families and the close partnership between patients and scientists have been a constant source of inspiration.”
Developing regenerative therapies for Huntington’s disease has required overcoming scientific challenges, including identifying therapeutic targets, optimising delivery strategies and addressing a slowly progressing condition. Advances in disease biology are helping move the field toward clinical evaluation.
As the study has only recently begun, investigators are primarily assessing safety, with exploratory measures evaluating potential signals for future research.
“The initial goal of this study is to establish safety,” Thompson said. “If future studies ultimately demonstrate that a one‑time cell therapy approach can slow disease progression, it could have meaningful implications for people living with Huntington’s disease. However, those questions can only be answered through careful clinical evaluation.”
